HIND

EX-99.1

2 ea030322801ex99-1.htm

PRESS RELEASE DATED AUGUST 25, 2026

Exhibit 99.1

Vyome Holdings Reports Second Quarter 2026 Results Highlighted By Advancement Of Lead

VT-1953 Program, Pipeline Expansion And Strong Balance Sheet

CAMBRIDGE, Mass., August 25, 2026 — Vyome Holdings, Inc. (“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the second quarter ended June 30, 2026, and provides a corporate update.

Krishna Gupta, Chairman of Vyome Holdings, said, “Vyome continues to execute with focus and discipline across its development programs while maintaining a methodical and conservative approach to capital allocation. During the quarter, we advanced our lead VT-1953 program, broadened our pipeline through the Impetis agreement and continued to strengthen our intellectual property portfolio. With a strong balance sheet and disciplined capital structure, we believe Vyome is well positioned to pursue its development priorities and create long-term shareholder value.”

Venkat Nelabhotla, Vyome President and Chief Executive Officer, stated, “VT-1953 remains our lead priority. The Phase 2 data presented this year demonstrated statistically significant improvements in malodor, the patient-reported impact of malodor on daily life, and lesion pain, with no treatment-emergent adverse events reported. In March 2026, we submitted a pre-IND briefing package to the FDA that included our proposed pivotal clinical study strategy for the treatment of malodor and other symptoms associated with malignant fungating wounds. During the second quarter of 2026, the Company received the FDA’s written response on the proposed clinical development program. The Company is incorporating the FDA’s feedback, preparing the appropriate supporting package, and plans to continue its engagement with the FDA through a Type C meeting to further advance the clinical development program.

“At the same time, we are selectively building additional opportunities around our core immuno-inflammatory strategy. Our agreement with Impetis adds two selective JAK inhibitor assets and provides potential access to important autoimmune and inflammatory disease categories. We intend to advance these opportunities in a disciplined manner with non-dilutive methods while keeping VT-1953 as our primary development focus. Importantly, we continue to maintain a clean capital structure with no debt, no preferred stock, and no toxic financing instruments. We believe this combination of focused clinical execution, pipeline optionality, and financial discipline provides a strong foundation for long-term shareholder value,” concluded Mr. Nelabhotla.

Second Quarter 2026 and Recent Corporate Highlights

●In March 2026, submitted a pre-IND briefing package to the FDA including the proposed pivotal clinical study strategy for VT-1953; received the FDA’s written response on the proposed clinical development program during the second quarter is incorporating the FDA’s feedback, preparing the appropriate supporting package, and plans to continue its engagement with the FDA through a Type C meeting to further advance the clinical development program.

●Presented Phase 2 clinical data on lead candidate VT-1953 topical gel for treatment of malignant fungating wounds (MFW) at the American Association for Cancer Research (AACR), including:

oStatistically significant reduction in malodor (primary endpoint)

oStatistically significant improvement in patient-reported impact of malodor on daily life

oStatistically significant improvement in lesion pain

oNo treatment-emergent adverse events

●Signed agreement with Impetis Biosciences Limited (“Impetis’) to in-license two selective JAK inhibitor assets designed for higher selectivity to potentially treat autoimmune and inflammatory conditions

●Received a granted Chinese patent covering formulation and therapeutic use claims related to VB-1953 topical gel program for treating inflammatory acne

Financial Results for the Quarter Ended June 30, 2026

●Cash and cash equivalents were approximately $7.9 million as of June 30, 2026, compared with approximately $5.0 million as of December 31, 2025

●Total current assets were approximately $8.2 million as of June 30, 2026

●Total stockholders’ equity was approximately $7.3 million as of June 30, 2026

●Total operating expenses for the quarter ended June 30, 2026, were approximately $874,000, including approximately $507,000 in research and development expenses and approximately $365,000 in selling, general, and administrative expenses

●Net loss attributable to common shareholders for the quarter ended June 30, 2026, was approximately $720,000, or approximately $0.10 per basic and diluted share

Complete financial results can be found in the Company’s recent Quarterly Report on Form 10-Q available at sec.gov.

About Vyome Holdings, Inc.:

Vyome is building the world’s premier platform spannin